<SEC-DOCUMENT>0001558370-25-009663.txt : 20250728
<SEC-HEADER>0001558370-25-009663.hdr.sgml : 20250728
<ACCEPTANCE-DATETIME>20250728170451
ACCESSION NUMBER:		0001558370-25-009663
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250728
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250728
DATE AS OF CHANGE:		20250728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		251156363

	BUSINESS ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20250728x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.0.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 7/28/2025 8:38:09 PM -->
<!-- iXBRL Library version: 1.0.9292.28120 -->
<!-- iXBRL Service Job ID: 3762ca79-6dc5-43b1-bc5a-83261df591b7 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20250728" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>PTC THERAPEUTICS, INC._July&#160;28, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityCentralIndexKey" id="Tc_7CkewqBlsUSgFvnygwklUA_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:AmendmentFlag" id="Tc_aCokRrvubUOe72eeyJMThQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20250728.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9d7520d6_f03c_4ef9_aad5_6e03cda5926f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:DocumentType" id="Narr_etj4WpKxd0W2fg_aaMzW8A"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_PeNxZsWKT0qlfrjyBwRhfg"><b style="font-size:9pt;font-weight:bold;">July&#160;28, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityRegistrantName" id="Narr_-VcPcWom-kCSsokdhnuw-A"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_Y2ADDD4HzkOX5uLjWd5amw_2_0"></a><a id="Tc_EAZnT7pFu0u7DnOyjxx8zg_2_2"></a><a id="Tc_leSz4MzN9USZ1fGZvVL3NA_2_4"></a><a id="Tc_4KtILpoouUW9ZZfWdAAVjg_3_0"></a><a id="Tc_9CTu2ptJ5k-F4wRotx5Stg_3_2"></a><a id="Tc_P5lNZozMykCLeAeJCzA6XA_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_TE1kSWK9SUSXaj55kVPZlA_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityFileNumber" id="Tc_KqKygaJ-a06HvgfuyBwCPw_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityTaxIdentificationNumber" id="Tc_unUgVFpJpUy4VfJzOxkP9Q_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_TvfT8X-ahE2chsXHOASCOg_2_0"></a><a id="Tc_0GpKdF4PQ0WlDjP03GplSQ_3_0"></a><a id="Tc_bgksTB7T8k-kHeE4KSi4_Q_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityAddressAddressLine1" id="Tc_kHRj7jRD4UGfyDKb6QYkxA_1_0"><b style="font-size:9pt;font-weight:bold;">500 Warren Corporate Center Drive</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityAddressCityOrTown" id="Narr_O4q6Q_fLfEmZ3Ti9AjAFOw"><b style="font-size:9pt;font-weight:bold;">Warren</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityAddressStateOrProvince" id="Narr_BjhSvMThVEO_J5oVfqNNfw"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:EntityAddressPostalZipCode" id="Tc_Hi92IhjmiU2nv24F-6xMgg_2_3"><b style="font-size:9pt;font-weight:bold;">07059</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:CityAreaCode" id="Narr_e46O-ar-rEO5Ivs4x4Ranw"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:LocalPhoneNumber" id="Narr_xsXXNCYhSkiLEuMz30T5yA"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_h6RjvaMMmkK01xis2iTPEw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_adeJr7yjTkW-VbAlK6YUuw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_OziWz6fbM0aHdR8hEhpn5g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_MVz3W_wQVkOspuuIM4_Jyg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_nRhVe8ZqbU2UwTir7XImgg_1_0"></a><a id="Tc_9prNhBZgHUGK9zXZsK_4Jg_1_2"></a><a id="Tc_F-Y5cFAQZU6Okil8Qrr4Yg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:Security12bTitle" id="Tc_-CSck9dpmkattJLIErmoFw_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" name="dei:TradingSymbol" id="Tc_jyPkDz5K20qyzqmeXZboZw_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_q3X3lLJSTUCzmzZeJUhJGA_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_tAEPim0O1kG6beVfeX-P4A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5fd4cb2b_3abd_4eb3_8b2a_a767d2be95c0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;7.01.&#160;Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July 28, 2025, PTC Therapeutics, Inc. (the &#8220;Company&#8221;), announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved Sephience&#8482; (sepiapterin) for the treatment of children and adults living with phenylketonuria (&#8220;PKU&#8221;). Sephience is indicated for the treatment of hyperphenylalaninemia in adult and pediatric patients one month of age and older with sepiapterin-responsive PKU. T<span style="color:#212529;background:#ffffff;">he full text of the press release issued in connection with the announcement is furnished as Exhibit&#160;99.1 to this Current Report on Form 8-K (this &#8220;Report&#8221;) and is incorporated by reference into this Item&#160;7.01. </span><span style="color:#212529;">The Company will host a&#160;</span>conference<span style="color:#212529;">&#160;call on July&#160;28, 2025 at 5:00 p.m. Eastern Time to discuss the approval. Instructions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">The information in this Report (including Item 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</p><a id="_753c3274_3b02_4005_b531_26af0bc8d6df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:14.95%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.9%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.13%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:14.95%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.9%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20250728xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated July 28, 2025 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:14.95%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.9%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;font-size:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d4e2a9a6_33b3_4c2a_b78d_f05547286d67"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: July 28, 2025</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20250728xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.0.0.141--><!--Created on: 7/28/2025 08:38:06 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:14.4pt;min-height:57.6pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><img src="tmb-20250728xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:76.18pt;width:125.09pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;background:#ffffff;">PTC Therapeutics Announces FDA Approval of Sephience&#8482; (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="background:#ffffff;">- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older &#8211;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;background:#ffffff;margin:0pt;">- PTC will host a conference call on Monday, July 28<sup style="font-size:8.25pt;vertical-align:top;">th</sup> at 5:00 pm ET -</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">WARREN, N.J</b><b style="font-weight:bold;">., July 28, 2025</b> -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE&#8482; (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive PKU. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><font style="visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">&#8220;We are excited to have reached this important milestone for those affected by PKU,&quot; said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. &quot;The broad labeling reflects the potential of Sephience to meet the significant unmet need of PKU patients. The Sephience clinical data along with our expertise in launching rare disease therapies position Sephience to become the future standard of care. Our experienced customer facing teams are ready to bring this therapy to children and adults with PKU in the United States as quickly as possible.&quot;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">The FDA approval is based on the evidence of significant efficacy and safety from the Phase&#160;<font style="white-space:pre-wrap;">3 APHENITY trial as well as durability of treatment effect in the APHENITY long-term extension study.   </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">&#8220;The approval marks an exciting milestone for the PKU community,&#8221; said Catherine Warren, Executive Director of the National PKU Alliance. &#8220;This progress brings renewed hope, and we are eager to see the positive impact this new treatment option will have on advancing care and potentially improving quality of life for individuals of all ages and PKU subtypes that respond to this therapy.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;">SEPHIENCE was recently granted marketing authorization by the European Commission. Review of approval applications is ongoing in several other countries including Japan and Brazil.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><font style="font-weight:bold;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Conference Call and Webcast </b><b style="font-weight:bold;"><br></b>PTC will hold a conference call Monday, July 28, 2025 at 5:00 pm ET to discuss this news. To access the call by phone, please click&#160;<b style="font-weight:bold;">here</b>&#160;to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">About SEPHIENCE&#8482; (sepiapterin)</b><br>SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients with phenylketonuria (PKU). Sephience is a natural precursor of the enzymatic co-factor BH4, a critical co-factor for phenylalanine hydroxylase (PAH). Through its mechanism of action, Sephience is able to effectively reduce blood phenylalanine (Phe) </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:14.4pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><img src="tmb-20250728xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:76.18pt;width:125.09pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">levels and has the potential to treat a broad range of PKU patients. Sephience is approved in the European Economic Area and the United States.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Indication and Important Safety Information </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 4.8pt 0pt;"><b style="font-weight:bold;">Indication</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 4.8pt 0pt;">SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE is to be used in conjunction with a phenylalanine (Phe)-restricted diet.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 4.8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 4.8pt 0pt;"><b style="font-weight:bold;">Contraindications</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 4.8pt 0pt;">None</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:15pt 0pt 4.8pt 0pt;"><b style="font-weight:bold;">Important Safety Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 11.25pt 0pt;">Treatment with SEPHIENCE should be directed by physicians knowledgeable in the management of PKU. Biochemical response to SEPHIENCE can only be determined by a therapeutic trial with careful monitoring of ongoing dietary and nutritional balance to ensure adequate Phe control.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:15pt 0pt 4.8pt 0pt;"><b style="font-weight:bold;">Warnings and Precautions</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Noto Sans Symbols';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Increased Bleeding: </b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">SEPHIENCE may increase the risk of bleeding. Bleeding events, including superficial hematomas, prolonged bleeding, and heavy menstrual bleeding have occurred in patients treated with SEPHIENCE. Inform patients about the risk of bleeding associated with SEPHIENCE and have patients follow up with their healthcare provider should such a bleeding event occur. Consider treatment interruption with SEPHIENCE in patients with active bleeding. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="border-top-style:none;font-family:'Noto Sans Symbols';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="border-top-style:none;padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Hypophenylalaninemia: </b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">Some pediatric patients receiving</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;"> </b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">SEPHIENCE experienced hypophenylalaninemia. Monitor blood Phe levels during treatment and modify the dosage of SEPHIENCE and/or dietary protein and Phe intake as needed to ensure adequate blood Phe level control. Frequent blood monitoring is recommended in the pediatric population.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin-bottom:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="border-top-style:none;font-family:'Noto Sans Symbols';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="border-top-style:none;padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Interaction with Levodopa: </b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">In a 10-year post-marketing safety surveillance program for a non-PKU indication using another drug that is a phenylalanine hydroxylase (PAH) activator, 3 patients with underlying neurological disorders experienced seizures, exacerbation of seizures, over-stimulation, and irritability during co-administration with levodopa. Monitor patients who are receiving levodopa for changes in neurological status during treatment with SEPHIENCE.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:4.8pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;padding-bottom:4.8pt;margin:0pt;"><b style="font-weight:bold;">Adverse Reactions</b></p><p style="border-top-style:none;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 4.8pt 0pt;">Most common adverse reactions with SEPHIENCE (&#8805;2% and &gt; placebo) were diarrhea, headache, abdominal pain, hypophenylalaninemia, feces discoloration, and oropharyngeal pain.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:15pt 0pt 4.8pt 0pt;"><b style="font-weight:bold;">Drug Interactions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e.g., trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:14.4pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><img src="tmb-20250728xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:76.18pt;width:125.09pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">reduce sepiapterin metabolism to BH<sub style="font-size:8.25pt;vertical-align:sub;">4</sub>. If concomitant use is not avoidable, monitor blood Phe levels.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">SEPHIENCE and PDE-5 inhibitors (e.g., sildenafil, vardenafil, or tadalafil) induce vasorelaxation and may reduce blood pressure. Monitor for signs and symptoms of hypotension.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">For medical information, product complaints, or to report an adverse event, please call 1<font style="font-family:'Cambria Math';">&#8209;</font>866<font style="font-family:'Cambria Math';">&#8209;</font>562<font style="font-family:'Cambria Math';">&#8209;</font>4620 or email at usmedinfo@ptcbio.com.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">You may also report adverse events directly to FDA at 1<font style="font-family:'Cambria Math';">&#8209;</font>800<font style="font-family:'Cambria Math';">&#8209;</font>FDA<font style="font-family:'Cambria Math';">&#8209;</font>1088 or www.fda.gov/medwatch.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Please see Full Prescribing Information.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">About Phenylketonuria</b><br><font style="background:#ffffff;">Phenylketonuria (PKU) is a rare, inherited metabolic disease, which affects the brain. It is caused by a defect in the gene that helps create the enzyme needed to break down phenylalanine (Phe). If left untreated or poorly managed, Phe&#8212;an essential amino acid found in all proteins and most foods&#8212;can build up to harmful levels in the body. This causes severe and irreversible disabilities, such as permanent intellectual disability, seizures, delayed development, memory loss, and behavioral and emotional problems. Newborns with PKU initially do not have any symptoms, but symptoms are usually progressive, and damage caused by toxic levels of Phe in the first few years of life is irreversible. Diagnosis of PKU usually takes place during newborn screening programs. There are an estimated 58,000 people living with PKU globally.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">About PTC Therapeutics, Inc.</b>&#160;<br>PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company&#39;s strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit&#160;www.ptcbio.com&#160;and follow on Facebook, X, and LinkedIn.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">For More Information:&#8239;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Investors:</b>&#160;<br>Ellen Cavaleri&#160;<br>+1 (615) 618-6228&#160;<br>ecavaleri@ptcbio.com<b style="font-weight:bold;">&#8239;</b>&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Media:</b>&#160;<br>Jeanine Clemente&#160;<br>+1 (908) 912-9406&#160;<br>jclemente@ptcbio.com<b style="font-weight:bold;">&#8239;</b>&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statement</b>&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:14.4pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><img src="tmb-20250728xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:76.18pt;width:125.09pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 12pt 0pt;">timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; expectations with respect to Sephience, including timing of commercialization and of potential regulatory decisions; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to Sephience, including any regulatory submissions and potential approvals, commercialization and the potential achievement of regulatory and sales milestones and contingent payments that PTC may be obligated to make; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Sephience.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20250728xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20250728xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "< /\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBFNZQJ69@JCDDG % #J*S+CQ%90Y
M$9ENW[):1-*3^*C _$U3;6=9N<_9=!:,=FO;E(\_@NXUSRKTUHG?T3?Y7.B-
M"H];6]6E^=C?HKDKBW\:7G^KN](T]?\ 8B>5A^)X_2J$W@_Q?=9\SQ@8\]H;
M4+_6N:6*J+X*,G]R_-HZ8X2F_CK17_@3_),[RBO,Y_AKXHER1XUNR?;>O\FK
M,N?ACXV3)A\6S2GL&NIE_J:Y9X[%1_YA9??'_,ZX8'"R_P"8J/W2_P CU^BO
M!-0\._$O1LL+N_NT7^.WNS+_ ..DY_2L5OB3XST2;R[F]N(W'\%U",_J*\^?
M$$:#MB*$X_+_ (8]"'#\JZOAZ\)?/_ASZ5HKP;2OC]J]N0M_8VUXG]Z/,;_U
M'Z5VFB?''0-3=8[L3:;(?XI5W)^8Z?B*[:&>8"OHJEGYZ?\  _$XJ^18_#ZN
MG=>6OX;_ ('HM%5['4+74X!-:7$5S$>CQ.&'Z58KW4U)73T/!:<79K4****8
M@HHHH **** "BBB@ HK\XOVJ?VOOBE\-/CEXB\.^']?CL])M&B$,+6<+E<QJ
M3RRDGDFO)?\ AOKXV?\ 0TP_^"^#_P"(KOC@ZDDI)K4#]=Z*_(C_ (;Z^-G_
M $-,/_@O@_\ B*5?V^_C6I!_X2B$^QT^#_XBJ^HU.Z _7:BORT\+?\%*OBEH
M]S&=6MM&UZV'WXY;8PNP]F0C!_ _2OLCX ?MJ>"/CK<Q:4OF>'?$CKD:;?."
MLI[B*08#_0@'VK"IAJE-7:T ^@Z*\^^/OBS4O WP>\4Z[H\XMM3L;-YH)60.
M%8=#@\&OS,_X;^^-7_0RV_\ X+X/_B:*6'G63<0/UTHK\B_^&_OC5_T,MO\
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M,C)<]342Q5&"?*]0/5_@/\)+#X)_##1O"UDD9EMX]]W<(N#/<-S(Y/?G@9Z
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MEC'LSA/S0TWX=>&)?V M1\5/H-@WB1-2\M=5,"_: OFQC ?KC!/YU[9\8/\
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M;C)[UYSX?_8K^#7A;6[+5],\'_9M0LI5F@F_M*[;8XZ'#2D'\141J0]ER2;
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M]%)Q:7*C\^)****S **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>tmb-20250728.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/28/2025 8:38:17 PM-->
<!--Modified on: 7/28/2025 8:38:17 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20250728" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:srt-roles="http://fasb.org/srt-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20250728" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250728_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250728_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20250728_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>tmb-20250728_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/28/2025 8:38:17 PM-->
<!--Modified on: 7/28/2025 8:38:17 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20250728.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>tmb-20250728_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/28/2025 8:38:17 PM-->
<!--Modified on: 7/28/2025 8:38:17 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>tmb-20250728_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.0.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/28/2025 8:38:17 PM-->
<!--Modified on: 7/28/2025 8:38:17 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20250728.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638893318974544205" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638893318974544205" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638893318974544205" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638893318974544205" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638893318974544205" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638893318974544205" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638893318974544205" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638893318974544205" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638893318974544205" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638893318974544205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638893318974544205" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638893318974554179" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638893318974554179" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638893318974554179" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638893318974554179" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638893318974554179" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638893318974554179" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638893318974554179" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638893318974554179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638893318974554179" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638893318974564177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638893318974564177" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638893318974564177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638893318974564177" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638893318974564177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638893318974564177" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638893318974564177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638893318974564177" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 28,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Warren Corporate Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20250728x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20250728.xsd</File>
    <File>tmb-20250728_def.xml</File>
    <File>tmb-20250728_lab.xml</File>
    <File>tmb-20250728_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20250728x8k.htm">tmb-20250728x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20250728x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20250728",
   "dts": {
    "schema": {
     "local": [
      "tmb-20250728.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20250728_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20250728_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20250728_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20250728x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250728x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20250728x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-25-009663-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-009663-xbrl.zip
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M8MQ=THR5:,)R03?),J>X+U$K-Y!V:QQ=^2\=/XBKFS?ZE:SMS?]02P,$%
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MT-*\;#V3;[W_Y&6!,R+W#6XR'G[W*\41WT?1WK\2]^VOVTVMRA5Z;DL-^:3
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M,C@N>'-D4$L! A0#%     @ F8C\6K['N"+> @  ]0H  !0
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M2P$"% ,4    " "9B/Q:R;<V(5T7  !W9P  %P              @ 'F*
M=&UB+3(P,C4P-S(X>&5X.3ED,2YH=&U02P4&      8 !@"* 0  >$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tmb-20250728x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20250728.xsd" xlink:type="simple"/>
    <context id="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_7CkewqBlsUSgFvnygwklUA_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_aCokRrvubUOe72eeyJMThQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_etj4WpKxd0W2fg_aaMzW8A">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_PeNxZsWKT0qlfrjyBwRhfg">2025-07-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_-VcPcWom-kCSsokdhnuw-A">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_TE1kSWK9SUSXaj55kVPZlA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_KqKygaJ-a06HvgfuyBwCPw_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_unUgVFpJpUy4VfJzOxkP9Q_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_kHRj7jRD4UGfyDKb6QYkxA_1_0">500 Warren Corporate Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_O4q6Q_fLfEmZ3Ti9AjAFOw">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_BjhSvMThVEO_J5oVfqNNfw">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_Hi92IhjmiU2nv24F-6xMgg_2_3">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_e46O-ar-rEO5Ivs4x4Ranw">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_xsXXNCYhSkiLEuMz30T5yA">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_h6RjvaMMmkK01xis2iTPEw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_adeJr7yjTkW-VbAlK6YUuw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_OziWz6fbM0aHdR8hEhpn5g">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_MVz3W_wQVkOspuuIM4_Jyg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_-CSck9dpmkattJLIErmoFw_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_jyPkDz5K20qyzqmeXZboZw_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Tc_q3X3lLJSTUCzmzZeJUhJGA_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_28_2025_To_7_28_2025_W-wdNQ4d3E-Lj5elU3QAjg"
      id="Narr_tAEPim0O1kG6beVfeX-P4A">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
